Priothera Moves Mocravimod Into Pivotal Trials
High Hopes For Leukemia Therapy
The Irish biotech has launched a Phase IIb/III trial of its sphingosine 1 phosphate receptor modulator mocravimod, expanding a mode of action that has been successful in autoimmune indications into the hematology space.
You may also be interested in...
The privately owned company currently earns most of its revenues in respiratory medicine in Europe, but has set its sights on expanding in rare diseases and the US market.
Novartis passed up the chance for further development of Kyorin's mocravimod for autoimmune diseases but newly formed Priothera is evaluating the S1P receptor modulator for acute myeloid leukemia patients undergoing hematopoietic stem cell transplantation.
The pipeline to treat the neurological disorder, which is characterized by uncontrolled rapid and repeated movements or sounds, is very thin but a couple of biotechs either side of the Atlantic are making progress.